Boundless Bio, Inc.
boundlessbio.comWhat Do They Do?
Develops small-molecule cancer drugs aimed at DNA amplification mechanisms in tumors, for patients with oncogene-amplified cancers.
10-K for FY2025, filed Mar 9, 2026
Sources
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 9, 2026
Sources
How Are They Changing?
Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 7, 2026
−$23.7MView ↗
- ▲ +51% (Loss)
- vs −$15.7M in Q2 FY2025
-
Aug 28, 2026
Boundless amended its merger agreement with Serapha
Sources
8-K, filed Aug 28, 2026
As previously announced, on June 22, 2026, Boundless Bio, Inc., a Delaware corporation (“Boundless Bio”), Boulder Merger Sub Corp., a…View ↗
-
Jun 23, 2026
Boundless agreed to merge with Serapha
The combined company plans to operate as Serapha Bio and focus on its base-editing therapy for alpha-1 antitrypsin deficiency.
Sources
8-K, filed Jun 23, 2026
SAN DIEGO and NEW YORK – June 23, 2026 – Boundless Bio, Inc. (Nasdaq: BOLD) and Serapha Bio, Inc., a privately held biotechnology company…View ↗
Loading...
Comments
